JP2023539742A - Ｐｃｓｋ９調節物質及びｌｄｌｒ調節物質による敗血症の治療 - Google Patents

Ｐｃｓｋ９調節物質及びｌｄｌｒ調節物質による敗血症の治療 Download PDF

Info

Publication number
JP2023539742A
JP2023539742A JP2023513460A JP2023513460A JP2023539742A JP 2023539742 A JP2023539742 A JP 2023539742A JP 2023513460 A JP2023513460 A JP 2023513460A JP 2023513460 A JP2023513460 A JP 2023513460A JP 2023539742 A JP2023539742 A JP 2023539742A
Authority
JP
Japan
Prior art keywords
seq
nucleic acid
pcsk9
acid molecule
set forth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023513460A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023539742A5 (https=
Inventor
ホロウィッツ、ジュリー
アンドレア ロッタ、ルカ
アレン レベズ フェレイラ、マヌエル
ダマスク、エイミー
ポールディング、チャールズ
マンヴェリアン、ガレン
カンター、マイケル
バラス、アリス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2023539742A publication Critical patent/JP2023539742A/ja
Publication of JP2023539742A5 publication Critical patent/JP2023539742A5/ja
Priority to JP2025155627A priority Critical patent/JP2026004359A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023513460A 2020-08-25 2021-08-25 Ｐｃｓｋ９調節物質及びｌｄｌｒ調節物質による敗血症の治療 Pending JP2023539742A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025155627A JP2026004359A (ja) 2020-08-25 2025-09-19 Ｐｃｓｋ９調節物質及びｌｄｌｒ調節物質による敗血症の治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063069789P 2020-08-25 2020-08-25
US63/069,789 2020-08-25
PCT/US2021/047502 WO2022046873A1 (en) 2020-08-25 2021-08-25 Treatment of sepsis with pcsk9 and ldlr modulators

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025155627A Division JP2026004359A (ja) 2020-08-25 2025-09-19 Ｐｃｓｋ９調節物質及びｌｄｌｒ調節物質による敗血症の治療

Publications (2)

Publication Number Publication Date
JP2023539742A true JP2023539742A (ja) 2023-09-19
JP2023539742A5 JP2023539742A5 (https=) 2023-10-26

Family

ID=77775030

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023513460A Pending JP2023539742A (ja) 2020-08-25 2021-08-25 Ｐｃｓｋ９調節物質及びｌｄｌｒ調節物質による敗血症の治療
JP2025155627A Pending JP2026004359A (ja) 2020-08-25 2025-09-19 Ｐｃｓｋ９調節物質及びｌｄｌｒ調節物質による敗血症の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025155627A Pending JP2026004359A (ja) 2020-08-25 2025-09-19 Ｐｃｓｋ９調節物質及びｌｄｌｒ調節物質による敗血症の治療

Country Status (10)

Country Link
US (2) US12378557B2 (https=)
EP (1) EP4204563A1 (https=)
JP (2) JP2023539742A (https=)
KR (1) KR20230057410A (https=)
CN (1) CN116171161A (https=)
AU (1) AU2021335200A1 (https=)
CA (1) CA3191030A1 (https=)
IL (1) IL300439A (https=)
MX (1) MX2023001912A (https=)
WO (1) WO2022046873A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2634837A (en) 2022-06-07 2025-04-23 Scribe Therapeutics Inc Compositions and methods for the targeting of PCSK9
CN119716057B (zh) * 2024-12-10 2025-07-15 中国人民解放军总医院 Pcsk6在诊断脓毒症中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013170367A1 (en) * 2012-05-17 2013-11-21 The University Of British Columbia Methods and uses for proprotein convert ase subtilisin kexin 9 (pcsk9) inhibitors
WO2020010186A1 (en) * 2018-07-06 2020-01-09 Derek Klarin Pcsk9 variants

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1471152A1 (en) 2003-04-25 2004-10-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Mutations in the human PCSK9 gene associated to hypercholesterolemia
KR100985090B1 (ko) 2008-05-23 2010-10-04 한국과학기술연구원 크라이센 노출 여부 확인용 바이오마커 및 이를 이용한확인 방법
JP5703218B2 (ja) 2008-08-14 2015-04-15 ネステク ソシエテ アノニム 満腹感、脂質代謝及び脂肪利用に影響を及ぼすための組成物及び方法
EP2488663A4 (en) 2009-10-16 2012-09-05 Genetics Invest Pty Ltd SENSITIVITY TO MACRONUTRIENT
WO2012048414A1 (en) 2010-10-12 2012-04-19 Mcmaster University A method of regulating plasma lipoproteins
WO2013043041A2 (en) 2011-09-21 2013-03-28 Infovalley® Group Of Companies Methods and compositions for diagnosing familial hypercholesterolemia
WO2014028946A2 (en) 2012-08-17 2014-02-20 The Broad Institute, Inc. Modulators of hepatic lipoprotein metabolism
TWI682780B (zh) 2013-05-30 2020-01-21 美商再生元醫藥公司 醫藥組成物用於製造治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途
EP3052521A1 (en) * 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
WO2015073709A2 (en) 2013-11-14 2015-05-21 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Detection of atherosclerotic cardiovascular disease risk and heart failure risk
WO2015073710A2 (en) 2013-11-14 2015-05-21 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES Detection of atherosclerotic cardiovascular disease risk and myocardial infarction risk
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
WO2015092393A2 (en) 2013-12-17 2015-06-25 Kymab Limited Human targets
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US9051378B1 (en) 2014-07-15 2015-06-09 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
CA2947127A1 (en) 2014-05-02 2015-11-19 Cerenis Therapeutics Holding Sa Hdl therapy markers
EP4328245A3 (en) 2014-07-15 2024-06-05 Kymab Ltd. Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
WO2016023916A1 (en) 2014-08-12 2016-02-18 Kymab Limited Treatment of disease using ligand binding to targets of interest
WO2016071701A1 (en) 2014-11-07 2016-05-12 Kymab Limited Treatment of disease using ligand binding to targets of interest
NL2014136B1 (en) 2015-01-14 2017-01-27 Stichting Katholieke Univ Annexin A2 SNP and von Willebrand Disease.
US10265379B2 (en) 2015-09-16 2019-04-23 Annabelle Rodriguez Oquendo Use of recombinant lymphocyte activation gene-3 as a companion therapeutic for patients at risk for cardiovascular disease and other chronic inflammatory diseases
WO2017218798A1 (en) 2016-06-15 2017-12-21 Boston Heart Diagnostics Systems and methods for diagnosing familial hypercholesterolemia
ES2871783T3 (es) * 2016-09-20 2021-11-02 Univ Aarhus Compuestos para el tratamiento de trastornos del metabolismo de las lipoproteínas
US10337070B2 (en) 2017-01-12 2019-07-02 Cardioforecast Ltd. Methods and kits for treating cardiovascular disease
US20190345557A1 (en) 2017-07-12 2019-11-14 The General Hospital Corporation Atrial fibrillation polygenic risk score
US20190017119A1 (en) 2017-07-12 2019-01-17 The General Hospital Corporation Genetic Risk Predictor
US20190341125A1 (en) 2017-07-12 2019-11-07 The General Hospital Corporation Inflammatory bowel disease polygenic risk score
US20190330698A1 (en) 2017-07-12 2019-10-31 The General Hospital Corporation Diabetes polygenic risk score
US20190345566A1 (en) 2017-07-12 2019-11-14 The General Hospital Corporation Cancer polygenic risk score
US11680296B2 (en) 2017-10-16 2023-06-20 Massachusetts Institute Of Technology Mycobacterium tuberculosis host-pathogen interaction
WO2019199684A1 (en) 2018-04-09 2019-10-17 The Regents Of The University Of Michigan Methods and systems for biocellular marker detection and diagnosis using a microfluidic profiling device
MX2020013994A (es) 2018-06-22 2021-05-27 Bluestar Genomics Inc Análisis de hidroximetilación de muestras de ácido nucleico sin células para asignación de tejido de origen, y métodos relacionados de uso.
US20210285050A1 (en) 2018-07-06 2021-09-16 United States Government As Represented By The Department Of Veterans Affairs Pde3b variants
JP2022507958A (ja) * 2018-11-27 2022-01-18 ノバルティス アーゲー 代謝障害の治療用のプロタンパク質転換酵素サブチリシン／ケキシン９型（ｐｃｓｋ９）阻害薬としての環状四量体化合物
EP3969620B1 (en) 2019-05-17 2025-06-25 Regeneron Pharmaceuticals, Inc. Genome-based methods for reducing cardiovascular risk
CN113874020A (zh) 2019-05-22 2021-12-31 基诺富公司 使用曲美替尼和标志物治疗神经退化性疾病的给药方法和剂量方案
US20200368239A1 (en) 2019-05-22 2020-11-26 Genuv Inc. Treatment of amyotrophic lateral sclerosis using trametinib
WO2021058597A1 (en) 2019-09-24 2021-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of determining whether a subject is at risk of developing arterial plaques
US20210113536A1 (en) 2019-10-21 2021-04-22 United States Government as Represented by the Department of Veteran Affairs Methods and compositions for detecting and treating venous thromboembolism

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013170367A1 (en) * 2012-05-17 2013-11-21 The University Of British Columbia Methods and uses for proprotein convert ase subtilisin kexin 9 (pcsk9) inhibitors
WO2020010186A1 (en) * 2018-07-06 2020-01-09 Derek Klarin Pcsk9 variants

Also Published As

Publication number Publication date
IL300439A (en) 2023-04-01
WO2022046873A1 (en) 2022-03-03
KR20230057410A (ko) 2023-04-28
US20260078378A1 (en) 2026-03-19
AU2021335200A9 (en) 2024-10-03
EP4204563A1 (en) 2023-07-05
JP2026004359A (ja) 2026-01-14
US12378557B2 (en) 2025-08-05
US20220064652A1 (en) 2022-03-03
AU2021335200A1 (en) 2023-04-27
CN116171161A (zh) 2023-05-26
MX2023001912A (es) 2023-07-10
CA3191030A1 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
US20260078378A1 (en) Treatment Of Sepsis With PCSK9 And LDLR Modulators
US11820982B2 (en) Treatment of ophthalmic conditions with son of Sevenless 2 (SOS2) inhibitors
US20230000897A1 (en) Treatment Of Cerebrovascular Disease With Neurogenic Locus Notch Homolog Protein 3 (NOTCH3) Agents
US20230192864A1 (en) Treatment Of Lung Conditions With Integrin Subunit Alpha 1 (ITGA1) Inhibitors
US12157891B2 (en) Treatment of uveitis with endoplasmic reticulum aminopeptidase 1 (ERAP1) inhibitors
US20250136996A1 (en) Treatment of smoking with cholinergic receptor nicotinic beta 3 subunit (chrnb3) inhibitors
US20240247267A1 (en) Treatment Of Stroke With 1,4-Alpha-Glucan-Branching Enzyme (GBE1) Inhibitors
KR20230152732A (ko) 링 핑거 단백질 213(rnf213) 억제제를 이용한 간 질환의 치료
US20230034093A1 (en) Treatment Of Cognitive Impairment With Alpha-N-Acetylgalactosaminide Alpha-2,6-Sialyltransferase 5 (ST6GALNAC5) Inhibitors
CN118613584A (zh) 使用内质网氨基肽酶1(erap1)抑制剂治疗葡萄膜炎
US20230023182A1 (en) Methods Of Treating Asthma With Solute Carrier Family 27 Member 3 (SLC27A3) Inhibitors
AU2022303368A1 (en) Treatment of hypertension with solute carrier family 9 isoform a3 regulatory factor 2 (slc9a3r2) inhibitors
KR20240067064A (ko) 레티쿨로칼빈-3[rcn3] 변이체 및 인터류킨-4 수용체 알파[il4r] 길항제를 이용한 천식의 치료
JP2024524554A (ja) ピエゾ型機械受容イオンチャネル成分１（ｐｉｅｚｏ１）アゴニストによる静脈瘤の処置
CN118265529A (zh) 使用camp应答元件结合蛋白3样3(creb3l3)抑制剂的肝病治疗
CN117597132A (zh) 用环指蛋白213(rnf213)抑制剂治疗肝病

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231018

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241029

A603 Late request for extension of time limit during examination

Free format text: JAPANESE INTERMEDIATE CODE: A603

Effective date: 20250310

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250314

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250624

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251216